FibroBiologics, Inc. Common Stock (FBLG)
FibroBiologics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $1.03, down 1.94% on the session, giving a market capitalisation of $2.2M. On trailing twelve-month figures it carries a trailing P/E of -0.18, a net margin of 0.0%. Its beta of 1.22 implies it has historically moved more than the broad market.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FibroBiologics, Inc. Common Stock is most often compared with the following Healthcare names: